Inspire Investing LLC Raises Stock Position in Glaukos Corporation $GKOS

Inspire Investing LLC raised its stake in shares of Glaukos Corporation (NYSE:GKOS) by 45.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,958 shares of the medical instruments supplier’s stock after acquiring an additional 1,239 shares during the period. Inspire Investing LLC’s holdings in Glaukos were worth $390,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in GKOS. Bessemer Group Inc. grew its holdings in Glaukos by 133.9% during the 1st quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 158 shares in the last quarter. Whipplewood Advisors LLC raised its position in Glaukos by 3,957.1% during the 1st quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 277 shares during the last quarter. First Horizon Advisors Inc. grew its stake in shares of Glaukos by 72.9% during the 1st quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier’s stock worth $37,000 after purchasing an additional 159 shares during the period. Versant Capital Management Inc grew its stake in shares of Glaukos by 583.9% during the 1st quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier’s stock worth $38,000 after purchasing an additional 327 shares during the period. Finally, Bayforest Capital Ltd acquired a new position in Glaukos during the first quarter worth about $141,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Price Performance

Shares of GKOS opened at $82.74 on Monday. The company has a market capitalization of $4.75 billion, a price-to-earnings ratio of -50.15 and a beta of 0.77. Glaukos Corporation has a fifty-two week low of $77.10 and a fifty-two week high of $163.71. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.51 and a quick ratio of 4.69. The business’s 50-day moving average is $93.48 and its 200-day moving average is $95.49.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.02. The company had revenue of $124.12 million for the quarter, compared to the consensus estimate of $115.49 million. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.The firm’s quarterly revenue was up 29.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.52) EPS. Glaukos has set its FY 2025 guidance at EPS. Equities research analysts expect that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on GKOS. William Blair raised shares of Glaukos to a “strong-buy” rating in a research note on Thursday, July 31st. BTIG Research restated a “buy” rating and issued a $118.00 price target on shares of Glaukos in a report on Wednesday, September 10th. UBS Group boosted their target price on shares of Glaukos from $125.00 to $134.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. Zacks Research downgraded shares of Glaukos from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 15th. Finally, Wells Fargo & Company increased their target price on shares of Glaukos from $86.00 to $92.00 and gave the stock an “equal weight” rating in a report on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $124.83.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.